On January 23, 2023, Innovid Corp. (the “Company”) announced a reduction of its global full-time headcount by approximately 10%. This headcount reduction reflects the Company’s continued focus on sustainable and profitable growth. It is expected that the implementation of the headcount reduction will be substantially complete by the end of the first quarter of 2023.
Boston Scientific Announces Late-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLX™ Left Atrial Appendage Closure Device
Today, Boston Scientific (NYSE:BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure
